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ABSTRACT
The prevalence of diabetes increased from year to year. The diabetic animal model was developed to
study the pathogenesis and treatment in diabetes. The aim of this study was to determine the profile of diabetic
blood glucose level  in rat  using a stratified dose streptozotocin (STZ-SD) and multi-low dose streptozotocin
(MLD-STZ) induction methods. 27 Wistar rats were divided into three groups, the control group, SD-STZ group,
and MLD-STZ group. The induction of experimental animal was using the method of SD-STZ and MLD-STZ for
five consecutive days intraperitoneally. The SD-STZ method using a stratified dose of 40, 35, 30, 25, and 20
mg/Kg of body weight for five days. MLD-STZ methods using a dose of 20 mg/Kg of body weight for five times.
The measurement of blood glucose level (BGL) and body weight (BW) in the animal was made before and on
days 2, 4, 7, and 14 after STZ induction. The results of this study indicate that the diabetic conditions (BGL ≥
300 mg/dl) on the SD-STZ induction method was more stable than MLD-STZ method, and no deaths occurred in
experimental animals.
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Diabetes is a chronic syndrome characterized by an
increased blood glucose level and urine secretion due
to  insulin  deficiency,  the  effect  of  insulin  action,  or
both [1]. The number of people with diabetes increases
in  line  with  population growth,  aging,  urbanization,
the increasing prevalence of obesity, and physical inac-
tivity [2]. 
The epidemiology study estimated that by 2030, the
prevalence  of  diabetes  mellitus  in  Indonesia  has
reached 21.3 million people [2]. This phenomenon has
become an important concern for public health, espe-
cially to be considered in dentistry treatment. 
Streptozotocin  (STZ)  (is  a  cytotoxic  methyl  ni-
trosourea  moiety (N-methyl-N-nitrosourea) which at-
tached to a glucose molecule (2-deoxyglucose). STZ is
a diabetogenic agent, used as an experimental of the
diabetic  animal  model.  STZ inhibit  insulin  secretion
and cause necrosis of the pancreatic beta cells [3].
STZ induction methods that have been developed
at this time are the single dose and multiple low doses
STZ with  various  doses.  The single dose  method of
STZ at a dose of 65 mg/kg intraperitoneally reported
to have limitations, such as the death of rats in each
group due to unknown causes [4]. MLD-STZ methods
at  40  mg/kg  dose  of  STZ  for  five  days  showed
significant diabetic condition. The BGL at week 3 was
334.16 ± 17.5 mg/dl and 325.7 ± 30.8 mg/dl at week 4,
and no deaths occurred in experimental animals [5].
MLD-STZ methods had been developed using a dose
of 20 mg/kg for five days [6]. The diabetic conditions
reported in the second week with BGL average of 549.2
± 11.76 mg/dl [7]. 
The failure of obtaining diabetic rats also due to a
decline in blood glucose levels in some experimental
animals after an increase in blood glucose levels >300
mg/dl [4,5]. A previous study has not been reported
whether the induction method used can produce a sta-
ble diabetic condition and did not decrease blood glu-
cose levels in animals due to unknown causes, so the
animal is not considered diabetic. Therefore, this study
will  develop  an  induction  method  using  a  stratified
dose  of  STZ  (SD-STZ)  for  5  consecutive  days.  The
doses are 40, 35, 30, 25, and 20 mg/kg of body weight
intraperitoneally.  This  method  is  expected  result  a
more  stable  condition  of  hyperglycemia  in  diabetic
conditions. 
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Rat Diabetic Blood Glucose Level Profile with Stratified Dose Streptozotocin (SD-STZ)
The aim of this study was to determine the profile
of  diabetes  blood  glucose  levels  with  the  induction
method  stratified  dose  streptozotocin  (STZ-SD)  and
multi low-dose streptozotocin (MLD-STZ). 
Experimental Animals and Samples 
Wistar  rats (Rattus norvegicus) were used in this
study. Inclusion criteria in this study are, (a) healthy
rats and no abnormalities, (b) four-month-old-male, (c)
weight 250-300 grams. Exclusion criteria are, (a) dis-
ability or disorder rats, (b) died during the study, (c)
the examination of blood glucose levels on day 3 has
not shown a hyperglycemia. 
The sample sizes in this study were 27 Wistar rats,
which  divided  into  three  groups,  the  control  group,
SD-STZ  treatment  group,  and  MLD-STZ  treatment
group. All the study procedures were conducted under
the guidelines  approved by the Ethics  Committee of
the Dentistry Faculty of Gadjahmada University,  Yo-
gyakarta, Indonesia. 
Preparation of Streptozotocin (STZ) stock solution 
STZ was dissolved in distilled water and then added
to one drop of 0.1 M citrate buffer to obtain STZ solu-
tion with a pH of 4.5 and stored at 4°C. 
Experimental Animals Treatment
After acclimatized for seven days, the animals were
performed  at  the  induction  of  the  MLD-STZ group
with a dose of 20 mg/kg in 5 times for five days. The
SD-STZ group was performed at  a stratified dose of
STZ intraperitoneally. The dose of STZ was started at
40, 35, 30, 25, and 20 mg/kg for five consecutive days.
Experimental animals were put in a cage and incubated
for 14 days. 
Measurement of Blood Glucose Level (BGL) and Body
Weight (BW) 
During incubation, the experimental animals were
observed blood glucose levels which taken from the tail
vein of a rat before and on days 2, 4, 7, and 14 after
the induction of STZ. Rats with diabetes are character-
ized by BGL  300 mg/dl. The body weight of experi≥ -
mental animals was also measured before and on days
2, 4, 7, and 14 after induction of STZ.
Observation 
The BGL was observed using a digital blood glu-
cose  level  and  Glucostick  (Gluco-Dr).  Experimental
animal body weight was measured using a digital scale
(Weston).
Statistical Analysis
Blood glucose levels (BGL) and body weight (BW)
of experimental animals was measured before and after
treatment. The data were analyzed using the t-test with
SPSS 20.0 software. 
Body Weight (BW)
The measurement of body weight in experimental
animals  before  and after  induction of  Streptozotocin
(STZ) is shown in Figure 1. From Figure 1 it can be
seen that  the average  of body weight  in the control
group was increased. Different results appear in either
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Figure 1. The average of body weight (gram) in the control, MLD-STZ, and SD-STZ groups. Measurements before induction (Pre),
measurements after induction at day 2 (H+2), 4 (H+4), 7 (H+7), and 14 (H+14). The body weight of SD-STZ group
experienced a sharp decline compared with the MLD-STZ group.
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MLD-STZ or SD-STZ group. The SD-STZ group expe-
rienced a sharp decline compared with the MLD-STZ
group.
Blood Glucose Levels (BGL) 
The measurement of blood glucose level in experi-
mental animals before and after the induction of STZ
was shown in Figure 2. Figure 2 showed the average of
blood glucose levels in the control group was in nor-
mal conditions. There was an increased of the MLD-
STZ group blood glucose levels at day four after induc-
tion (374.2 mg/dl). The BGL at day 14 after induction
was decreased back (169.1 mg/dl).
In the SD-STZ group, there were an increased of
blood glucose levels on day 2 (464.7 mg/dl) and day 14
(563 mg/dl).  The average  of  blood glucose  levels  in
SD-STZ group at day 7 and 14 were decreased by 511.9
mg/dl and 401 mg/dl, but still in the category of dia-
betic rats. These results indicate that the BGL in the
SD-STZ group was more stable than MLD-STZ group
above 300 mg/dl, both on days 2, 4, 7 and 14. 
Statistical analysis showed a significant difference of
BGL before  and after  induction in  the  SD-STZ and
MLD-STZ  group  (p<0.05).  Statistical  analysis  also
showed no significant differences in the SD-STZ group
between H+4 - H+14 and H+7 - H+14 (p>0.05). 
This study used a diabetic rat model of 2, 4, 7 and
14 days. The difference of time was to determine the
differences in blood glucose levels because of a short
period of diabetes. The aged conversion of rat model
with human age showed that 20-day old rats are ap-
proximately  equal  to  two  years  of  human  life  [8].
Therefore, in 14 days diabetic rat model was analogous
to  a  human  who  have  diabetes  for  more  than  17
months. 
The results of this study showed that the average of
body weight in the control group was increased. Differ-
ent  results  appear  in  both  MLD-STZ  and  SD-STZ
groups.  The  SD-STZ  group  experienced  a  sharp
decline  compared  with  MLD-STZ group  (Figure  1).
The results  are  consistent  with previous studies  that
the STZ induced diabetic rats shown a significant de-
crease in body weight at week 2 after STZ induction
[9]. The loss of body weight because of induction of
STZ was associated with an increase in muscle wasting
(gluconeogenesis  and glycogenolysis)  and the  loss  of
tissue proteins [10,11]. Insulin deficiency can cause a
variety of metabolic disorders, including the increased
blood glucose level, decreased in protein content and
increased  of  cholesterol  as  well  as  triglyceride  levels
[12]. 
The results of this study showed that the average of
blood glucose levels in SD-STZ group was more stable
above 300 mg/dl compared with the MLD-STZ group
(Figure  2).  These  results  indicated  that  the  SD-STZ
method produces  hyperglycemia  conditions  (BGL ≥
300 mg/dl) were more stable than using the MLD-STZ
methods. Statistical analysis showed a significant differ-
ence of BGL before and after induction, both in SD-
STZ and MLD-STZ group. Statistical  analysis results
indicated that no significant  differences  in the blood
glucose levels on days 2, 4, 7, and 14 with SD-STZ and
MLD-STZ induction methods.
Blood glucose levels were used to diagnose diabetes.
Hyperglycemia in diabetes was caused by insulin secre-
tion deficiency by pancreatic beta cell dysfunction or
insulin act resistance in the liver and muscle, or combi-
nation of both [13]. 
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Figure 2.  The average of blood glucose level (mg/dl) in the control, MLD-STZ, and SD-STZ groups. The blood glucose level in the 
SD-STZ group was more stable than MLD-STZ group above 300 mg/dl, both on days 2, 4, 7 and 14. 
Rat Diabetic Blood Glucose Level Profile with Stratified Dose Streptozotocin (SD-STZ)
Diabetic condition on SD-STZ has shown a more
stable  hyperglycemia  condition.  This  was  probably
caused by a greater dose of STZ. However, it gave rise
toward smaller doses. The stratified dose was given as
an adaptation response in a diabetic rat model of STZ
administration.  The Less stable hyperglycemia condi-
tion in MLD-STZ induction method was possibly be-
cause of repeated administration of smaller doses, re-
sulting in a decrease in blood glucose levels at days 7
and 14 after induction. A blood glucose level condition
which less stable and reversible was possible happened
because of the regeneration process of pancreatic beta
cell damage. Some of the material that caused diabetes
in experimental animals such as alloxan can cause a
spontaneous regeneration of pancreatic beta cells [14]. 
Streptozotocin (STZ) is a diabetogenic agent, which
is used as an experimental diabetes mellitus in labora-
tory animals. STZ inhibit insulin secretion and cause
necrosis of the pancreatic beta cells [3]. STZ inhibit the
biosynthesis and secretion of insulin through interfer-
ence  with  the  glucose  metabolism  and  oxygen  con-
sumption [3]. Streptozotocin-induced diabetes mellitus
(STZ-DM) which is caused by the pancreatic beta cell
destruction was similar  to  type 1 of  diabetes  in hu-
mans.  It  was  characterized  by  hyperglycemia,  glyco-
suria,  polyphagia,  hypoinsulinemia,  hyperlipidemia,
and body weight loss. STZ-DM also shows some com-
plications that include increased susceptibility to infec-
tion, cardiovascular disease, retinopathy, changes in an-
giogenesis, wound healing disorders, decreased expres-
sion of growth factors, and decreased bone formation
[15,16]. 
The advantages of STZ induction on diabetic con-
ditions were more stable than other materials. A dia-
betic rat model of STZ induction can be used as an ex-
perimental study for the long term. The disadvantages
of diabetic STZ induction are the elevation of mortality
rate, and the failure to get diabetic conditions [14]. 
From this study, it can be concluded that the rat
diabetic conditions (BGL  300 mg/dl) of SD-STZ in≥ -
duction  method  were  more  stable  than  MLD-STZ
method. There were no deaths occurred in experimen-
tal animals.
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